LimFlow

LimFlow announced today that it closed an oversubscribed Series D financing round worth proceeds of $40 million (€36 million).

Paris-based LimFlow develops the LimFlow system for minimally invasive treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). The system uses a family of transcatheter products designed to optimize the perfusion of the critically ischemic foot to potentially avoid major amputation, resolve pain and promote wound healing.

According to a news release, the financing will be used for follow-up for the Promise II U.S. pivotal trial necessary for garnering FDA approval. LimFlow completed enrollment in the FDA investigational device exemption (IDE) trial last month. Proceeds will also support the commercialization of the system for deep vein arterialization.

New investors Longitude Capital, Soleus Capital Management and an undisclosed strategic investor joined the round. Existing major s…

LimFlow announced today that it completed patient enrollment in the Promise II pivotal trial of its LimFlow system.

Paris-based LimFlow designed its LimFlow system to reestablish materialization in deep veins for chronic limb-threatening ischemia (CLTI) — a severe form of peripheral artery disease (PAD) — patients who have exhausted other methods and face major amputation of their lower limbs.

The multi-center, prospective, single-arm Promise II study across multiple U.S. sites enrolled 105 no-option CLTI patients. Endpoints include amputation-free survival at six months, limb salvage and wound healing. Subjects will be followed out to three years.

LimFlow also completed enrollment in its CLariTI study of approximately 200 high-risk and no-option CLTI patients. That study will track the clinical progression of CLTI and incidence of death, amputation and revascularization attempts in patients undergoing standard medical management for the disease over a o…